Leqvio(inclisiran)
Leqvio (inclisiran) is an oligonucleotide pharmaceutical. Inclisiran was first approved as Leqvio on 2020-12-09. It is used to treat hypercholesterolemia in the USA. It has been approved in Europe to treat dyslipidemias and hypercholesterolemia.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Leqvio
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| leqvio | New Drug Application | 2023-07-07 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypercholesterolemia | HP_0003124 | D006937 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
INCLISIRAN SODIUM, LEQVIO, NOVARTIS | |||
| 2026-12-22 | NCE | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Inclisiran Sodium, Leqvio, Novartis | |||
| 10851377 | 2036-08-25 | U-3652 | |
| 10125369 | 2034-08-18 | DS, DP | U-3652 |
| 8106022 | 2029-12-12 | DS, DP | U-3652 |
| 8828956 | 2028-12-04 | DS, DP | U-3652 |
| 9370582 | 2028-12-04 | DS, DP | U-3652 |
| 10806791 | 2028-12-04 | DP | |
| 10131907 | 2028-08-24 | DS, DP | U-3652 |
| 8222222 | 2027-12-29 | U-3652 | |
| 8809292 | 2027-05-10 | DS, DP | U-3652 |
| 11530408 | 2024-05-18 | DP | |
| 9708615 | 2024-03-08 | DP | |
| 10273477 | 2024-03-08 | DP | |
| 10669544 | 2024-03-08 | DP | |
HCPCS
Code | Description |
|---|---|
| J1306 | Injection, inclisiran, 1 mg |
Clinical
Clinical Trials
44 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypercholesterolemia | D006937 | HP_0003124 | — | 1 | 1 | 7 | 1 | 5 | 15 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | 1 | 1 | — | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperlipoproteinemia type ii | D006938 | EFO_0004911 | E78.00 | — | 4 | 6 | — | 1 | 11 |
| Homozygous familial hypercholesterolemia | D000090542 | — | — | — | 1 | 2 | — | — | 3 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | 1 | — | — | 1 |
| Heart disease risk factors | D000082742 | — | — | — | — | 1 | — | — | 1 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | 1 | — | — | 2 | 3 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperlipidemias | D006949 | HP_0003077 | E78.5 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carotid stenosis | D016893 | — | — | — | — | — | — | 1 | 1 |
| Aortic valve disease | D000082862 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Inclisiran |
| INN | inclisiran |
| Description | Inclisiran, sold under the brand name Leqvio, is a medication used for the treatment of high low-density lipoprotein (LDL) cholesterol and for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk-equivalents, and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA (siRNA) that acts as an inhibitor of a proprotein convertase, specifically, inhibiting translation of the protein PCSK9.
|
| Classification | Oligonucleotide |
| Drug class | Antilipemic agent |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1639324-58-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3990033 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB14901 |
| UNII ID | UOW2C71PG5 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Leqvio – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,263 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use